BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

Please provide your email address to receive an email when new articles are posted on . Nontuberculous mycobacterial (NTM) lung disease is a chronic and debilitating condition, and although considered ...

HONOLULU -- Whether patients with nontuberculous mycobacterial (NTM) lung disease respond to antibiotic treatment seemed to be related to their microbiome profile, a small study found. Out of 14 ...

The Baylor Medicine NTM Infection Program brings together specialists that can help you identify, understand, and manage NTM lung infections. As a leading center for comprehensive NTM care, we aim to ...

RHB-204 Phase 3 study in pulmonary NTM infections is planned to be initiated in the coming weeks--Orphan Drug Designation, along with RHB-204’s FDA QIDP priority designation, will extend U.S.

RHB-204 Orphan Drug designation and QIDP designation extend potential market exclusivity up to 12 years post-approval and provide eligibility for Fast-Track development and NDA Priority Review TEL ...

A phase 3 trial evaluating a nebulized clofazimine inhalation suspension (MNKD-101) for the treatment of refractory nontuberculous mycobacterial (NTM) lung disease has been discontinued. The ...

"The treatment of MAC lung disease is challenging, with a significant need for new therapies that improve upon the current standard of care and offer options to patients who previously have not been ...

Analyst Jeff Jones of Oppenheimer reiterated a Buy rating on AN2 Therapeutics, Inc. (ANTX – Research Report), with a price target of $28.00. Jeff Jones has assigned a Buy rating to AN2 Therapeutics, ...